After the announcement of Pulmonary Fibrosis treatment in India Glenmark has announced today about receiving approval for Sirolimus tablets, 0.5mg, 1mg, and 2mg.In a regulatory filing, Glenmark said ” Glenmark Pharmaceuticals Inc., USA (Glenmark) has received
final approval by the United States Food & Drug Administration (U.S. FDA) for Sirolimus Tablets, 0.5 mg, 1 mg and 2 mg, the generic version of Rapamune®1 Tablets, 0.5 mg, 1 mg, and 2 mg, of PF Prism CV.”
In recent years, India has made significant strides in the fight against cancer, with an…
As we age, our cognitive abilities naturally decline, but diet has emerged as a key…
In a significant move toward revolutionizing patient care, a panel discussion on Artificial Intelligence (AI)-based…
Breast cancer remains one of the leading causes of cancer-related deaths among women worldwide. Early…
Airport Proximity: Can living near an airport increase your risk of a heart attack? A…
Antimicrobial resistance (AMR), the ability of bacteria, fungi, and parasites to resist the effects of…